Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06738849

EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation

Led by DiappyMed · Updated on 2025-06-18

154

Participants Needed

16

Research Sites

107 weeks

Total Duration

On this page

Sponsors

D

DiappyMed

Lead Sponsor

S

Sanoia

Collaborating Sponsor

AI-Summary

What this Trial Is About

EkiYou-Study-2 is an interventional multicenter randomised controlled clinical investigation according to EU 2017/745. It is conducted in 154 adults with diabetes and treated by multiple daily insulin injections that will be followed for 6 months. After a randomization, participants will receive for 6 months EkiYou V2 Digital Therapy that will help them to estimate their daily bolus and basal insulin doses. This device weekly adjusts insulin parameters including : basal insulin dose, insulin to carb ratios and correction factor. The control group will stay with their standard care, and after the first three months of control period, they will receive EkiYou V2 for the last three months. The aim of this study is to examine the performance of the EkiYou V2 Digital Therapy compared with conventional methods for people with diabetes treated with multi-injections as part of a basal-bolus regimen. We also aim to assess the level of satisfaction and user experience with the EkiYou application, as well as the quality of life of study participants.

CONDITIONS

Official Title

EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be aged 18 or over
  • Have type 1, type 2, or pancreatogenous diabetes
  • Have been treated with multi-injection basal/bolus insulin therapy for at least 6 months
  • Use a compatible rapid insulin such as Novorapid, Humalog, Apidra, Asparte Sanofi, Fiasp, or Lyumjev
  • Use a compatible long-acting insulin such as Lantus, Abasaglar, Toujeo, Levemir, or Tresiba
  • Have been using a continuous glucose monitoring device like Dexcom G6, Dexcom One, Dexcom One+, or FreeStyle Libre for at least 3 months
  • Have given physician access to glucose data via a data management platform
  • For type 2 diabetes patients on hypoglycemia-inducing agents other than insulin, have no dosage changes for at least 3 months
  • Have recorded at least 70% of CGM data over a 14-day window near inclusion
  • Have a smartphone running Android 5.0 or higher or iOS 12.0 or higher connected to internet and able to receive CGM data
  • Able to read or use a smartphone without visual impairment requiring special typography
  • For patients of childbearing potential, have a pregnancy test before inclusion or use effective contraception
  • Be affiliated with a French social security scheme
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women
  • Type 1 diabetic patients treated with hypoglycemia-inducing agents other than insulin
  • Insulin-resistant patients prescribed daily insulin doses over 1 U/kg/day or more than 200 U/day
  • Patients with very low insulin requirements (less than 15 U/day)
  • Patients with gastroparesis
  • History of diabetic ketoacidosis or severe level 3 hypoglycemia needing third-party help within 6 months before inclusion
  • Pancreatic disease due to chronic ethanolism
  • Any medical condition that may interfere with the study protocol as judged by the investigator
  • Patients unable to be monitored for 3 months
  • Intellectual disability affecting use of the application or completion of questionnaires
  • Participation in another clinical trial or use of unauthorized drugs within 4 weeks before screening
  • Participation in another research study with an ongoing exclusion period
  • Under guardianship or curatorship
  • Imprisoned or deprived of liberty

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

APHP Avicennes

Bobigny, France

Actively Recruiting

2

CHU CAEN

Caen, France

Actively Recruiting

3

IDNC

Chartres, France

Actively Recruiting

4

CHSF Corbeil-Essonnes

Corbeil-Essonnes, France

Actively Recruiting

5

Cabinet Dr Picard

Dijon, France

Actively Recruiting

6

GH Le Havre - Hôpital Jacques Monod

Le Havre, France

Actively Recruiting

7

CHU Limoges - Dupuytren

Limoges, France

Actively Recruiting

8

Fondation Ambroise Paré / HEM

Marseille, France

Actively Recruiting

9

Cabinet Dr Navaranne

Mérignac, France

Actively Recruiting

10

University Hospital, Montpellier

Montpellier, France

Actively Recruiting

11

APHP - Hôpital La Pitié Salpêtrière

Paris, France

Actively Recruiting

12

CH Périgueux

Périgueux, France

Actively Recruiting

13

Cabinet Dr Diedisheim

Saint-Cyr-sur-Loire, France

Actively Recruiting

14

Cabinet Dr Gervaise

Saint-Cyr-sur-Loire, France

Actively Recruiting

15

CHU Toulouse - Hôpital Rangueil

Toulouse, France

Actively Recruiting

16

Clinique Pasteur

Toulouse, France

Actively Recruiting

Loading map...

Research Team

O

Omar Diouri, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here